ERBB2 and breast carcinoma: Because inhibition of the PI3K/AKT/mTOR axis results in enhanced HER2 signalling in HER2-overexpressing breast cancer, especially increased expression of HER2 and HER3 [23], targeting both pathways could prevent the development of resistance.